Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Early puberty is more common in girls and African-American children, possibly due to nutrition, obesity, stress, and environmental factors, and is treated with hormone therapy.

The document concludes that PCOS in adolescents is complex and requires comprehensive care to manage its symptoms and associated health risks.

Ovarian stromal hyperplasia can cause high testosterone in postmenopausal women and is treated by removing the ovaries.

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Different anti-androgen medications can help treat excessive hair growth, but the right choice depends on accurate diagnosis.

Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

The document concludes that hirsutism can be managed with various treatments tailored to the individual, potentially improving quality of life.

The document concludes that treating androgen excess needs patience, managing expectations is important, and many drugs used are not officially approved, suggesting cosmetic options for mild cases.

Removing both ovaries can treat increased testosterone and related symptoms in postmenopausal women with ovarian hyperthecosis.

The document suggests various treatments for PCOS, including medication for menstrual issues, insulin resistance, and excess hair, as well as fertility treatments, while highlighting the need for personalized care and lifestyle changes.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

More research is needed on the health effects of hormone therapy for transgender and nonbinary people.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.

Early diagnosis and treatment of PCOS in teenagers can help prevent more severe adult PCOS.

The document concludes that correct diagnosis and management of PCOS are important, and more research is needed on its risks and treatments.

Cyproterone acetate with ethinyl estradiol is effective for treating skin symptoms related to high androgen levels, like in PCOS.

The woman's surgery lowered her testosterone and improved scalp hair loss but did not change her excessive body hair.

The girl's unexpected pubic hair growth led to a diagnosis different from complete androgen insensitivity syndrome.

Gene mutations can cause problems in male genital development.

Ovarian vein sampling helped diagnose rare ovarian tumors causing high testosterone, and surgery to remove the tumors lowered the testosterone levels.

Testosterone treatment effectively causes male physical development in transgender male adolescents but may lead to side effects like acne, higher BMI and blood pressure, lower good cholesterol, and decreased bone density.

The chapter explains the causes of excessive hair growth and masculinization in women and how to measure hormone levels related to these conditions.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

Metformin can start ovulation and may lower 17P response in PCOS, but six months is too short to improve hair growth or change body fat distribution.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.